Hod M, Jovanovic L
Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tikva and Tel-Aviv University, Israel.
Int J Clin Pract Suppl. 2010 Feb(166):47-52. doi: 10.1111/j.1742-1241.2009.02278.x.
In the USA, depending upon the diagnosis criteria used, 135,000-200,000 women annually develop gestational diabetes mellitus, adding to the number of pregnant women already suffering from either type 1 or type 2 diabetes. Maternal hyperglycaemia and the resultant fetal hyperinsulinaemia are central to the pathophysiology of diabetic complications of pregnancy. These complications include congenital malformations and an increase in neonatal intensive care unit admission and birth trauma. In addition, there is an increased rate of accelerated fetal growth, neonatal metabolic complications and risk for stillbirth. Importantly, during the last century there were two breakthroughs in diabetes management and monitoring that changed the course of treatment: the discovery of insulin and the progress in the understanding of glucose monitoring. As technology has evolved, both glucose monitoring and insulin administration can now be achieved in a continuous fashion. In this review of the literature we focus on the utility of new technologies in the management and monitoring of diabetes in pregnancy.
在美国,根据所使用的诊断标准,每年有13.5万至20万妇女患妊娠期糖尿病,这使已经患有1型或2型糖尿病的孕妇人数增加。母亲高血糖以及由此产生的胎儿高胰岛素血症是妊娠糖尿病并发症病理生理学的核心。这些并发症包括先天性畸形、新生儿重症监护病房入院率增加和出生创伤。此外,胎儿生长加速、新生儿代谢并发症和死产风险的发生率也有所增加。重要的是,在上个世纪,糖尿病管理和监测有两项突破改变了治疗进程:胰岛素的发现和血糖监测认识上的进步。随着技术的发展,现在血糖监测和胰岛素给药都可以以连续的方式实现。在这篇文献综述中,我们重点关注新技术在妊娠糖尿病管理和监测中的应用。